Background and Purpose
The CLEAR-IVH program is assessing the efficacy of intraventricular recombinant tissue Plasminogen Activator (rtPA) for spontaneous intraventricular hemorrhage (IVH). This subanalysis assesses the effect of dose of rtPA by region on clearance of IVH.
Methods
Sixty-four patients within 12–24 hours of spontaneous IVH were randomized to placebo, 0.3mg, 1mg or 3mg of rtPA twice daily via an extraventricular drain. Twelve subregions of the ventricles were scored from 0–4. Effect of dose on IVH clearance to 50% (t50) of baseline score was compared by survival analysis for all regions combined and by subregion. Models including ventricular region, dose and baseline score were compared by Cox-Proportional Hazards.
Results
IVH score reduced faster across all regions with increasing rtPA dose (t50: log-rank p<0.0001; placebo-11.43 days, 95%CI 5.68–17.18; 0.3mg– 3.19d, 1.00–5.38; 1mg– 3.54d, 0.45–6.64; 3mg– 2.59d, 1.72–3.46). In the combined models, dose and baseline score were independently associated with reduction in IVH score, which was quickest in the midline ventricles, then the anterior half of the lateral ventricles and slowest in the posterior half of the lateral ventricles (t50: p<0.0001; rtPA dose: HR=1.47, 1.30–1.67; midline vs anterior-lateral HR=1.71, 1.08–2.71; midline vs posterior-lateral HR=4.05, 2.46–6.65; baseline score HR=0.96, 0.91–1.01), with a significant interaction between dose and ventricular region (p=0.005).
Conclusions
rtPA accelerates resolution of intraventricular hemorrhage. This effect is dose-dependent, is greatest in the midline ventricles and least in the posterior-lateral ventricles.
Clinical Trial Registration
http://www.clinicaltrials.gov: NCT00650858.